Business / Finance

RSS

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Handheld ultrasound device from Signostics receives 510K clearance from the FDA

Handheld ultrasound device manufacturer Signostics has received a major boost with 510(k) clearance from the US Food and Drug Administration (FDA) to market its new Signos RT to the lucrative American market.

7 May 2013

Cost-effective endoscopic system for urological procedures launched by Cook Medical

A new, cost-effective endoscopic option is now available to urologists. Physicians can use the Flexor® Vue™ Deflecting Endoscopic System during urological procedures to access and visualize body cavities or organs.

7 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

Perrigo net sales increase 18% to $920M in third quarter 2013

Perrigo Company today announced results for its third quarter ended March 30, 2013.Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share.

7 May 2013

Nuvo Research intends to proceed with its proposed share consolidation

Nuvo Research Inc. (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.

7 May 2013

Biocryst reports financial results for first quarter 2013

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013.

7 May 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.

7 May 2013

Hospital for Special Surgery signs agreement with Brazilian healthcare organization

Clinical pathways and quality initiatives leading to world class outcomes are the foundation of a far-reaching agreement between New York-based Hospital for Special Surgery, the recognized leader in orthopedics, rheumatology and related specialties, and Amil Par, the largest managed healthcare organization in Brazil, on behalf of Hospitalys Ortopedia, its newly opened orthopedic center in Rio de Janeiro.

7 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

Comprehensive Care Closes $5 million Senior Secured Credit Facility with TCA

Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare Funds, and managed care companies, today announced that it has closed a $5 million Senior Secured Credit Facility with TCA Global Credit Master Fund (TCA).

6 May 2013

National Health Investors announces its normalized Funds From Operations

National Health Investors, Inc. announced today its normalized Funds From Operations ("FFO"), its normalized Funds Available for Distribution ("FAD") and net income attributable to common stockholders for the three months ended March 31, 2013.

6 May 2013

ApolloMed net revenues climbed 52.2% to $7.8 million during fiscal 2013

Apollo Medical Holdings, Inc., an integrated physician-driven healthcare delivery company that puts 'Patients First,' today announced its fiscal year-end results for the three and twelve months ended January 31, 2013.

5 May 2013

U.S. Department of Justice clears Aetna's proposed acquisition of Coventry Health Care

Aetna today announced the U.S. Department of Justice has cleared Aetna's proposed acquisition of Coventry Health Care, Inc. Aetna expects to complete its acquisition of Coventry within the next three business days.

4 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

Cambrex sales increase by 5.7% in first quarter 2013

Cambrex Corporation reports results for the first quarter ended March 31, 2013.

3 May 2013

BioLife Solutions licenses specific areas of intellectual property to Janssen

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has licensed specific areas of its intellectual property to Janssen Research & Development, LLC.

2 May 2013

RainDance Technologies announces closing of $20M Series E financing round

RainDance Technologies, Inc., the Digital Biology Company, today announced the closing of a $20 million Series E financing round. The company also announced that Myriad Genetics, Inc. has joined as a new strategic equity investor.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013